Ribonucleotide reductase as a therapeutic target for drug repurposing as anthelmintics

被引:2
|
作者
Panesso, Marcelo Pasa [1 ,2 ,3 ]
Cancela, Martin
Cora, Renato Kulakowski [1 ,2 ,3 ]
Paes, Jessica Andrade [1 ,2 ,3 ]
Paludo, Gabriela Prado [1 ,2 ,3 ]
Ferreira, Henrique Bunselmeyer [1 ,2 ,4 ]
机构
[1] Univ Fed Rio Grande do Sul UFRGS, Ctr Biotecnol, Lab Genom Estrutural & Func, Porto Alegre, Brazil
[2] Ctr Biotecnol, Lab Biol Mol Cestodeos, UFRGS, Porto Alegre, Brazil
[3] Univ Fed Rio Grande do Sul, Ctr Biotecnol, Programa Posgrad Biol Celular & Mol, Porto Alegre, Brazil
[4] Univ Fed Rio Grande do Sul, Inst Biociencias, Dept Biol Mol & Biotecnol, Porto Alegre, Brazil
关键词
Nucleotide synthesis; Echinococcus granulosus; Helminthiasis; Druggability; Drug repurposing; IN-VITRO; ECHINOCOCCUS; HYDROXYUREA; METABOLISM;
D O I
10.1016/j.exppara.2023.108641
中图分类号
R38 [医学寄生虫学]; Q [生物科学];
学科分类号
07 ; 0710 ; 09 ; 100103 ;
摘要
Visceral cestodiases, like echinococcoses and cysticercoses, are zoonoses of worldwide distribution and are responsible for public health problems in many countries, especially in underdeveloped regions. Current treatments have low efficiency and there are few drugs currently in use for chemotherapy, making the development of new anthelmintics an urgent matter. The nucleotide salvage pathways are the only ones available for nucleotide synthesis in cestodes and other parasitic helminths, and, here, we used in silico approaches to assess the potential of the enzymes in these pathways as targets for drug repurposing as anthelminthics. First, a genomic survey allowed to identify a repertoire of 28 enzymes of the purine and pyrimidine salvage pathways from the cestode Echinococcus granulosus sensu stricto. Regarding purines, the parasite relies on salvaging free bases rather than salvaging nucleosides. Pyrimidines, on the other hand, can be salvaged from both bases and nucleosides. Druggability of the parasite enzymes was assessed, as well as the availability of commercial inhibitors for them. Druggable enzymes were then ranked according to their potential for drug repurposing and the 17 most promising enzymes were selected for evolutionary analyses. The constructed phylogenetic trees allowed to assess the degree of conservation among ortholog enzymes from parasitic helminths and their mammalian hosts. Positive selection is absent in all assessed flatworm enzymes. A potential target enzyme for drug repurposing, ribonucleotide reductase (RNR), was selected for further assessment. RNR 3D-modelling showed structural similarities between the E. granulosus and the human orthologs suggesting that inhibitors of the human RNR should be effective against the E. granulosus enzyme. In line with that, E. granulosus protoscolices treated in vitro with the inhibitor hydroxyurea had their viability and DNA synthesis reduced. These results are consistent with nucleotide synthesis inhibition and confirm the potential of a nucleotide salvage inhibitors for repurposing as an anthelmintic.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Antifungal Drug Repurposing
    Kim, Jong H.
    Cheng, Luisa W.
    Chan, Kathleen L.
    Tam, Christina C.
    Mahoney, Noreen
    Friedman, Mendel
    Shilman, Mikhail Martchenko
    Land, Kirkwood M.
    ANTIBIOTICS-BASEL, 2020, 9 (11): : 1 - 29
  • [42] Perspectives on Drug Repurposing
    Schcolnik-Cabrera, Alejandro
    Juarez-Lopez, Daniel
    Duenas-Gonzalez, Alfonso
    CURRENT MEDICINAL CHEMISTRY, 2021, 28 (11) : 2085 - 2099
  • [43] Editorial: Drug Repurposing
    Pantziarka, Pan
    Andre, Nicolas
    FRONTIERS IN MEDICINE, 2019, 6
  • [44] Disulfiram in glioma: Literature review of drug repurposing
    Zhong, Shiyu
    Liu, Shengyu
    Shi, Xin
    Zhang, Xudong
    Li, Kunhang
    Liu, Guojun
    Li, Lishuai
    Tao, Shanwei
    Zheng, Bowen
    Sheng, Weichen
    Ye, Ziyin
    Xing, Qichen
    Zhai, Qingqing
    Ren, Lijie
    Wu, Ying
    Bao, Yijun
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [45] Drug Repurposing Approaches to Combating Viral Infections
    Trivedi, Jay
    Mohan, Mahesh
    Byrareddy, Siddappa N.
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (11) : 1 - 14
  • [46] Drug repurposing and human parasitic protozoan diseases
    Andrews, Katherine T.
    Fisher, Gillian
    Skinner-Adams, Tina S.
    INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE, 2014, 4 (02): : 95 - 111
  • [47] Leishmaniasis treatment: update of possibilities for drug repurposing
    Andrade-Neto, Valter Viana
    Cunha-Junior, Edezio Ferreira
    Faioes, Viviane dos Santos
    Martins, Thais Pereira
    Silva, Raphaela Lopes
    Leon, Leonor Laura
    Torres-Santos, Eduardo Caio
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2018, 23 : 967 - 996
  • [48] Biochemical Characterization of the Split Class II Ribonucleotide Reductase from Pseudomonas aeruginosa
    Crona, Mikael
    Hofer, Anders
    Astorga-Wells, Juan
    Sjoberg, Britt-Marie
    Tholander, Fredrik
    PLOS ONE, 2015, 10 (07):
  • [49] Repurposing of Drug Candidates for Treatment of Skin Cancer
    Cortes, Hernan
    Reyes-Hernandez, Octavio D.
    Alcala-Alcala, Sergio
    Bernal-Chavez, Sergio A.
    Caballero-Floran, Isaac H.
    Gonzalez-Torres, Maykel
    Sharifi-Rad, Javad
    Gonzalez-Del Carmen, Manuel
    Figueroa-Gonzalez, Gabriela
    Leyva-Gomez, Gerardo
    FRONTIERS IN ONCOLOGY, 2021, 10
  • [50] Drug Repurposing for Drug Development in Stroke
    Fagan, Susan C.
    PHARMACOTHERAPY, 2010, 30 (07): : 51S - 54S